Malignant hematological diseases with liver failure as the primary manifestation: a report of 7 cases

Abstract

Abstract: Objective To investigate the clinical features of malignant hematological diseases with liver failure as the initial manifestation. Methods The clinical data including clinical symptoms, laboratory markers, imaging features of 7 malignant hematological cases with acute or subacute liver failure as the initial manifestation diagnosed at our hospital from January 1, 2017 to January 1, 2022 were analyzed retrospectively. Results All the 7 patients were female, with an average age of 7-65 years. They all had typical symptoms and signs of liver failure. Seven cases had fever in the course of the disease, 4 patients had rash, 4 patients had lymphadenopathy, and 6 patients had splenomegaly. During the course of the disease, leukopenia, anemia or thrombocytopenia occurred in 7 cases. Imaging findings were lymphadenopathy, splenomegaly, bone invasion and so on. Bone marrow cytology indicated hemophagocytic syndrome, lymphoma cell.Conclusion Liver failure might be the initial manifestation of patients with hematological malignancies. There is a high misdiagnosis rate in these patients because of the nontypical clinical representations. Cytological examination of bone marrow should be performed as soon as possible in suspicious patients.

Key words: Hematological malignancy, Liver failure, Hemophagocytic syndrome, Lymphoma, Malignant histiocytosis

LAI Man, WANG Su-dan, SHEN Lin, LIU Hai-xia. Malignant hematological diseases with liver failure as the primary manifestation: a report of 7 cases[J]. Chinese Hepatolgy, 2023, 28(1): 33-36.

References

[1] 中华医学会感染病学分会肝衰竭及人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版). 临床肝胆病杂志, 2019, 35(01):38-44.
[2] Singh MM, Pockros PJ. Hematologic and oncologic diseases and the liver. Clin Liver Dis,2011, 15(1):69-87.
[3] Rich NE, Sanders C, Hughes RS, et al. Malignant infiltration of the liver presenting as acute liver failure. Clin Gastroenterol Hepatol, 2015, 13(5):1025-1028.
[4] Meier JA, Bokemeyer A, Cordes F, et al. Serum levels of ferritin and transferrin serve as prognostic factors for mortality and survival in patients with end-stage liver disease: a propensity score-matched cohort study. United European Gastroenterol J, 2020, 8(3):332-339.
[5] Minoia F, Davì S, Horne A, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol, 2014, 66(11):3160-3169.
[6] Allen CE, Yu X, Kozinetz CA, et al. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer, 2008, 50(6):1227-1235.
[7] Emmenegger U, Frey U, Reimers A, et al. Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes. Am J Hematol, 2001, 68(1):4-10.
[8] Lin TF, Ferlic-Stark LL, Allen CE, et al. Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality. Pediatr Blood Cancer, 2011, 56(1):154-155.
[9] Emmenegger U, Schaer DJ, Larroche C, et al. Haemophagocytic syndromes in adults: current concepts and challenges ahead. Swiss Med Wkly, 2005, 135(21-22):299-314.
[10] Carter SJ, Tattersall RS, Ramanan AV. Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment. Rheumatology (Oxford), 2019, 58(1):5-17.
[11] Al-Samkari H, Berliner N. Hemophagocytic Lymphohistiocytosis. Annu Rev Pathol, 2018, 13:27-49.
[12] Larroche C. Hemophagocytic lymphohistiocytosis in adults: diagnosis and treatment. Joint bone spine, 2012, 79(4):356-361.
[13] Tang WP, Zhong N, Chen ZW, et al. Clinical characteristics of liver dysfunction in patients with hemophagocytic syndrome. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2019, 27(4):1297-1304.
[14] Valade S, Azoulay E, Galicier L, et al. Coagulation disorders and bleedings in critically Ill patients with hemophagocytic lymphohistiocytosis. Medicine (Baltimore), 2015, 94(40):e1692.
[15] 王昭. 恶性组织细胞病的再认识. 中华血液学杂志, 2017, 38(09):806-808.
[16] Kheyri Z, Ali Asgari A, Zare Mehrjerdi A, et al. Fulminant hepatic failure due to primary hepatic lymphoma: a case report. Middle East J Dig Dis, 2013, 5(3):168-170.
[17] Romacho López L, León Díaz FJ, Sánchez Pérez B, et al. Acute liver failure caused by primary non-hodgkin's lymphoma of the liver. Transplant Proc, 2016, 48(9):3000-3002.
[18] Shah I, Vyas N, Reynolds JA. Natural killer-like T-cell lymphoma: a rare cause of acute liver failure. ACG Case Rep J, 2019, 6(7):e00145.
[19] Hafner A, Eaton DB. Acute liver failure with severe lactic acidosis secondary to infiltrative diffuse large B-cell lymphoma: an imaging-negative presentation. Cureus, 2020, 12(8):e10110.
[20] Shibata J, Kurahashi S, Naito T, et al. Diffuse large B cell lymphoma primarily presenting as acute liver failure in a surviving patient. J Community Hosp Intern Med Perspect, 2019, 9(2):135-139.
[21] El Nouwar R, El Murr T. Primary hepatic diffuse large B-cell lymphoma mimicking acute fulminant hepatitis: a case report and review of the literature. Eur J Case Rep Intern Med, 2018, 5(6):000878.